First-line treatment options for patients with metastatic hormone-sensitive prostate cancer (HSPC) are divided into two groups: androgen receptor signaling inhibitor (ARSI)-based doublet therapy and ...
Significant strides have been made in the frontline treatment of patients with advanced clear cell renal cell carcinoma (ccRCC). There are multiple standard-of-care doublet regimens consisting of ...
For men with metastatic castration-sensitive prostate cancer (mCSPC), a combination of three drugs may not always be better than two drugs, say researchers. Contemporary androgen deprivation therapy ...
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma Treatment with the triplet regimen of ...
Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting 33% ORR and 67% disease control observed with ...
The addition of chemotherapy to Gilead's Trodelvy and Merck's Keytruda didn't appear to offer more benefit in first-line non-small cell lung cancer. (Josh Edelson/AFP) Gilead Sciences has been looking ...
A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients. Over the past 14 years, ...
Please provide your email address to receive an email when new articles are posted on . Enrollment for a randomized phase 2 trial designed to compare a triplet regimen and doublet regimen for certain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results